S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NYSE:ENZ

Enzo Biochem - ENZ Stock Forecast, Price & News

$1.35
-0.05 (-3.57%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.34
$1.47
50-Day Range
$1.16
$1.98
52-Week Range
$1.11
$3.51
Volume
59,350 shs
Average Volume
56,218 shs
Market Capitalization
$65.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Enzo Biochem MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
0.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Enzo Biochem in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$213,520 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.26 out of 5 stars

Medical Sector

989th out of 1,026 stocks

Medical Laboratories Industry

22nd out of 24 stocks

ENZ stock logo

About Enzo Biochem (NYSE:ENZ) Stock

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

Massive “Heist” Could Sweep U.S. Banks in 2023
Wall Street professor warns FBI and U.S. Pentagon about a banking scheme that could soon cause a financial panic in all 50 states
Rhodamine 123 Market Share Likely to Grow At a CAGR
Massive “Heist” Could Sweep U.S. Banks in 2023
Wall Street professor warns FBI and U.S. Pentagon about a banking scheme that could soon cause a financial panic in all 50 states
ENZ.DF - | Stock Price & Latest News | Reuters
Enzo Biochem, Inc. (ENZ) Q1 2023 Earnings Call Transcript
See More Headlines
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Company Calendar

Last Earnings
12/12/2022
Today
2/08/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
7/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
451
Year Founded
1976

Profitability

Net Income
$-18,260,000.00
Pretax Margin
-26.89%

Debt

Sales & Book Value

Annual Sales
$107.07 million
Book Value
$1.12 per share

Miscellaneous

Free Float
41,168,000
Market Cap
$65.77 million
Optionable
Optionable
Beta
0.87

Social Links


Key Executives

  • Hamid Erfanian
    Chief Executive Officer & Director
  • Kara Cannon
    Chief Operating Officer
  • Patricia Eckert
    Chief Financial Officer
  • Dieter Schapfel
    Chief Medical Director
  • Matthew Kupferberg
    Secretary & General Counsel













ENZ Stock - Frequently Asked Questions

How have ENZ shares performed in 2023?

Enzo Biochem's stock was trading at $1.43 at the start of the year. Since then, ENZ stock has decreased by 5.6% and is now trading at $1.35.
View the best growth stocks for 2023 here
.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 344,100 shares, an increase of 9.1% from the December 15th total of 315,300 shares. Based on an average trading volume of 66,600 shares, the short-interest ratio is currently 5.2 days. Currently, 1.0% of the shares of the company are short sold.
View Enzo Biochem's Short Interest
.

When is Enzo Biochem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our ENZ earnings forecast
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) posted its quarterly earnings results on Monday, December, 12th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter. The medical research company had revenue of $18.28 million for the quarter. Enzo Biochem had a negative net margin of 26.89% and a negative trailing twelve-month return on equity of 38.65%.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, James G Wolf, Kara Cannon and Peter J Iv Clemens.
View institutional ownership trends
.

How do I buy shares of Enzo Biochem?

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $1.35.

How much money does Enzo Biochem make?

Enzo Biochem (NYSE:ENZ) has a market capitalization of $65.77 million and generates $107.07 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Enzo Biochem have?

The company employs 451 workers across the globe.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.

This page (NYSE:ENZ) was last updated on 2/9/2023 by MarketBeat.com Staff